Boston Medical Center

Running trials

• Not yet recruiting

  Anti-Interleukin-6 (IL6) in Calciphylaxis

  NCT07708038· Phase 1· Boston Medical Center· Source

• Not yet recruiting

  The Community Paramedic Response and Overdose Outreach With Supportive Medical-Legal Services Study

  NCT07216963· Duke University· Source

• Not yet recruiting

  Boston Medical Center Ultrasound Decongestion Study in Heart Failure

  NCT07096726· Boston Medical Center· Source

• Not yet recruiting

  Cilostazol for Prevention of Recurrent Stroke Trial

  NCT07174414· Phase 3· Stanford University· Source

• Recruiting

  A Randomized Placebo-procedure Controlled Trial of the Enhancor System (PULmonary Artery Denervation) to Evaluate Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease

  NCT07214376· Pulnovo Medical, Inc.· Source

• Recruiting

  Longitudinal Study of Retinal Function in Eyes Treated for Diabetic Macular Edema With Anti-VEGF Agents

  NCT07567833· Phase 4· Jaeb Center for Health Research· Source

• Recruiting

  Study of GS-0415 and How It Works in People With HIV

  NCT07719491· Phase 1· Gilead Sciences· Source

• Recruiting

  A US Study That Observes How Parkinson's Disease Changes Over Time in Patients Who Still Have Movement Symptoms Despite Taking Parkinson's Medications

  NCT07330258· Bayer· Source

• Recruiting

  Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease

  NCT07549698· Phase 1/2· CRISPR Therapeutics AG· Source

• Recruiting

  Behavior Analytic Support of Needle-related Hospital Visits for Autistic Patients

  NCT06712784· Boston Medical Center· Source

• Recruiting

  EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)

  NCT07287670· Phase 2· Mediar Therapeutics· Source

• Recruiting

  A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

  NCT07351045· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Stepped Care for Posttraumatic Stress Disorder Study

  NCT06947538· Boston Medical Center· Source

• Recruiting

  Delirium in Neurodegenerative Disease Patients: A Music Therapy Intervention for Hospital Care

  NCT07137949· Boston Medical Center· Source

• Recruiting

  A Study of Brenipatide in Participants With Opioid Use Disorder

  NCT07420283· Phase 2· Eli Lilly and Company· Source

• Recruiting

  Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)

  NCT07224360· Phase 2· CSL Behring· Source

• Recruiting

  A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma

  NCT07219212· Phase 1· Johnson & Johnson Enterprise Innovation Inc.· Source

• Enrolling by invitation

  SafeHeal Colovac Anastomosis Protection Device Evaluation Pivotal Study

  NCT07116668· SafeHeal Inc· Source

• Recruiting

  Improving Diabetes Care With Strategies For Addressing Health-Related Social Needs and Community Partnerships

  NCT07043426· Boston Medical Center· Source

• Recruiting

  REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants

  NCT07213778· Phase 3· Regeneron Pharmaceuticals· Source

• Recruiting

  Teclistamab-Daratumumab in AL Amyloidosis

  NCT07110844· Phase 2· Rajshekhar Chakraborty, MD· Source

• Recruiting

  Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)

  NCT07101094· Bristol-Myers Squibb· Source

• Recruiting

  US Benchmarking Clinical Study

  NCT07215715· eMyosound SAS· Source

• Recruiting

  Improving Hypertension Control in Safety-Net Settings: The Boston Hypertension Equity Alliance in Treatment

  NCT06948838· Boston Medical Center· Source

• Recruiting

  Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR

  NCT06790784· Phase 3· Jaeb Center for Health Research· Source

• Recruiting

  Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX)

  NCT07100990· Phase 3· Mayo Clinic· Source

• Recruiting

  Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

  NCT06532279· Phase 2· NRG Oncology· Source

• Recruiting

  Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

  NCT06589804· Phase 3· National Cancer Institute (NCI)· Source

• Recruiting

  A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

  NCT06615479· Phase 3· Juno Therapeutics, Inc., a Bristol-Myers Squibb Company· Source

• Recruiting

  A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease

  NCT06925542· Phase 1· CRISPR Therapeutics· Source

• Recruiting

  Alleviant ALLAY-HFrEF Study

  NCT06812533· Alleviant Medical, Inc.· Source

• Recruiting

  Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL

  NCT06806033· Phase 2· Hoffmann-La Roche· Source

• Recruiting

  Hybrid Closed Loop Effectiveness Trial in Adults With Type 1 Diabetes

  NCT06236607· Boston Medical Center· Source

• Recruiting

  A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease

  NCT06612268· Phase 3· Novo Nordisk A/S· Source

• Active, not recruiting

  IDEAL: Efficacy of Porcine Placental Extracellular Matrix Augmented Plus Standard of Care (SOC) Versus SOC Alone for the Management of Diabetic Foot Ulcers

  NCT06616844· ConvaTec Inc.· Source

• Recruiting

  Sensory Outcomes in Active Substance Users

  NCT06639438· Boston Medical Center· Source

• Recruiting

  StrokeNet Thrombectomy Endovascular Platform

  NCT06289985· Medical University of South Carolina· Source

• Recruiting

  A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia

  NCT06609226· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

  NCT06588478· Phase 2· Loxo Oncology, Inc.· Source

• Recruiting

  A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer

  NCT06457503· Phase 4· Coherus Oncology, Inc.· Source

• Active, not recruiting

  Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis

  NCT06655896· Phase 2· Novartis Pharmaceuticals· Source

• Recruiting

  The RAPID - PE Study: RESCUE Advanced Protocol for the Treatment of Pulmonary Embolism

  NCT06433011· Thrombolex, Inc.· Source

• Recruiting

  LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

  NCT06632444· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Non-Invasive Monitoring Methods in Patients With Acute Brain Injury

  NCT06504238· Boston Medical Center· Source

• Recruiting

  Safety and Effectiveness of Mechanical Thrombectomy Using the Anaconda ANA Funnel Catheter

  NCT06370182· Anaconda Biomed S.L.· Source

• Active, not recruiting

  A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)

  NCT06581198· Phase 2· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma

  NCT06413498· Phase 3· Kite, A Gilead Company· Source

• Recruiting

  A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)

  NCT06292780· Phase 1/2· Regeneron Pharmaceuticals· Source

• Enrolling by invitation

  Improving Outcomes and Reducing Disparities for Patients With Inflammatory Bowel Disease Through Epidemiology and Enhanced Disease Management

  NCT06424769· University of North Carolina, Chapel Hill· Source

• Recruiting

  A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease

  NCT06481306· Phase 1/2· Bristol-Myers Squibb· Source

Showing 50 of 162.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Stroke11 recruiting
• Amyloidosis6 recruiting
• Heart failure6 recruiting
• Chronic kidney disease4 recruiting
• Head and neck cancer4 recruiting
• Lung cancer4 recruiting
• Opioid use disorder4 recruiting
• Sickle cell disease3 recruiting
• Atrial fibrillation2 recruiting
• Childhood cancers2 recruiting
• Colorectal cancer2 recruiting
• Coronary artery disease2 recruiting
• Deep vein thrombosis and pulmonary embolism2 recruiting
• Diabetic eye disease2 recruiting
• High blood pressure2 recruiting
• HIV2 recruiting
• Multiple myeloma2 recruiting
• Peripheral artery disease2 recruiting
• Systemic sclerosis (scleroderma)2 recruiting
• Triple-negative breast cancer2 recruiting
• Type 1 diabetes2 recruiting
• Type 2 diabetes2 recruiting
• Autism1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Crohn's disease1 recruiting
• Delirium1 recruiting
• Dermatomyositis and polymyositis (myositis)1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Follicular lymphoma1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Gout1 recruiting
• Hodgkin lymphoma1 recruiting
• Hypertrophic cardiomyopathy1 recruiting
• Immune thrombocytopenia (ITP)1 recruiting
• Lupus (SLE)1 recruiting
• Mild cognitive impairment1 recruiting
• Myocarditis1 recruiting
• Obesity1 recruiting
• Optic neuritis1 recruiting
• Parkinson disease1 recruiting
• Post-traumatic stress disorder (PTSD)1 recruiting
• Pulmonary arterial hypertension1 recruiting
• Schizophrenia1 recruiting
• Ulcerative colitis1 recruiting
• Vascular dementia1 recruiting

Closed trials

• Terminated

  Open-Label Extension Study to Pioneer Study 6058-SCD-101

  NCT07401823· Phase 2· Fulcrum Therapeutics· Source

• Completed

  Innovative Automated Insulin Delivery System for Type 2 Diabetes

  NCT06853990· Deka Research and Development· Source

• Recruiting

  A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer

  NCT06562543· Phase 4· Takeda· Source

• Completed

  Retention and Re-Engagement in Treatment for Addiction Following Serious Injection Related Infections (RETAIN)

  NCT06489535· Boston Medical Center· Source

• Completed

  Web-administered STAIR for Patients on Behavioral Health Waitlists

  NCT06431022· Boston Medical Center· Source

• Terminated

  Conversational Agents to Improve HPV Vaccine Acceptance in Primary Care (ECA-HPV)- Clinical Trial

  NCT06367699· Tufts Medical Center· Source

• Completed

  RECOVER-SLEEP: Platform Protocol

  NCT06404086· Phase 2· Duke University· Source

• Completed

  A Novel Social Emotional Learning Curriculum for Youth With Epilepsy

  NCT06427967· Boston Medical Center· Source

• Withdrawn

  Lactobacillus Lozenges as Preventative Care in Low-grade Dysplasia

  NCT05707702· Phase 3· Boston Medical Center· Source

• Completed

  SafeHeal Diverting Ileostomy Pivotal Study

  NCT06152276· SafeHeal Inc· Source

• Withdrawn

  Mobile Application to Create Healthy Food Preparation Habits for Patients With Diabetes and Prediabetes

  NCT05726409· Boston Medical Center· Source

• Completed

  RECOVER-NEURO: Platform Protocol to Measure the Effects of Cognitive Dysfunction Interventions on Long COVID Symptoms

  NCT05965752· Duke University· Source

• Completed

  Refinement and Adaption of Reinforcement Learning to Personalize Behavioral Messaging for Healthy Habits

  NCT05742685· Brigham and Women's Hospital· Source

• Completed

  RECOVER-VITAL: Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID Symptoms

  NCT05595369· Phase 2· Kanecia Obie Zimmerman· Source

• Completed

  INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes

  NCT05904743· Phase 4· Mannkind Corporation· Source

• Completed

  A Randomized Trial Evaluating Control-IQ+ Technology in Adults With Type 2 Diabetes

  NCT05785832· Tandem Diabetes Care, Inc.· Source

• Terminated

  A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer

  NCT05678257· Phase 2· NuCana plc· Source

• Completed

  Transitioning Together Boston

  NCT05599711· Boston Medical Center· Source

• Terminated

  A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)

  NCT05592275· Phase 2· Eli Lilly and Company· Source

• Recruiting

  PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia

  NCT05313165· LimFlow, Inc.· Source

• Terminated

  Total Joint Arthroplasty (TJA) Weight Loss Study

  NCT05156762· Boston Medical Center· Source

• Completed

  Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)

  NCT05298423· Phase 3· Merck Sharp & Dohme LLC· Source

• Terminated

  Multi-Center, Prospective, Randomized Controlled Trial Evaluating SkinTE® in the Treatment of Wagner 2 DFUs

  NCT05372809· Phase 3· PolarityTE· Source

• Completed

  Tuberculosis - Learning the Effect of Parasites and Reinforcing Diets

  NCT05048485· Boston Medical Center· Source

• Completed

  A Hybrid Effectiveness Implementation Study of Latino/a Alcohol and Drug Users

  NCT04771650· Boston University Charles River Campus· Source

• Completed

  A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes With and Without Ibalizumab

  NCT05388474· Theratechnologies· Source

• Completed

  A Randomized, Controlled Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical Reperfusion System (SUMMIT MAX)

  NCT05018650· Route 92 Medical, Inc.· Source

• Completed

  Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pociredir

  NCT05169580· Phase 1· Fulcrum Therapeutics· Source

• Completed

  Pilot Testing PREschooler Care, Community Resources, Advocacy, Referral, Education (PRE-CARE)

  NCT04999982· Ann & Robert H Lurie Children's Hospital of Chicago· Source

• Completed

  Digital Health Weight Management Among Public Housing Residents

  NCT04852042· Tufts Medical Center· Source

• Completed

  Pilot Study of Biopsy Scanner for Evaluation of Bronchoscopic Small Biopsy Specimens to Determine Adequacy

  NCT05393154· Aquyre Bioscience, Inc· Source

• Terminated

  Assessment of Wound Closure Comparing Synthetic Hybrid-Scale Fiber Matrix With Standard of Care in Treating Diabetic Foot Ulcers (DFU) and With Living Cellular Skin Substitute in Treating Venous Leg Ulcers (VLU)

  NCT04927702· Acera Surgical, Inc.· Source

• Completed

  Improving Medical Decision Making for Older Patients With End Stage Renal Disease

  NCT04347629· Tufts Medical Center· Source

• Completed

  Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study

  NCT03911739· T. John Winhusen, PhD· Source

• Completed

  Synuclein-One Study

  NCT04700722· CND Life Sciences· Source

• Completed

  A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia

  NCT04278924· Phase 2· Takeda· Source

• Completed

  A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes

  NCT04560998· Phase 3· Novo Nordisk A/S· Source

• Completed

  Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)

  NCT04428151· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  Medication Treatment for Opioid Use Disorder in Expectant Mothers

  NCT03918850· Phase 3· T. John Winhusen, PhD· Source

• Completed

  Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study

  NCT03911466· T. John Winhusen, PhD· Source

• Completed

  A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers and in Participants With Sickle Cell Disease

  NCT04536792· Phase 1· Agios Pharmaceuticals, Inc.· Source

• Completed

  Sickle Cell Disease and CardiovAscular Risk - Red Cell Exchange Trial (SCD-CARRE)

  NCT04084080· Phase 3· University of Pittsburgh· Source

• Completed

  Cabozantinib and Nivolumab for Carcinoid Tumors

  NCT04197310· Phase 2· Dana-Farber Cancer Institute· Source

• Completed

  Safety and Efficacy of ActiGraft Pro Compared to Standard of Care in DFUs

  NCT04185558· RedDress Ltd.· Source

• Completed

  A Mobile Gaming App to Improve ART Adherence for Youth

  NCT03760211· Rhode Island Hospital· Source

• Completed

  HEALing Communities Study

  NCT04111939· RTI International· Source

• Completed

  Kids FACE FEARS Comparative Effectiveness Research

  NCT03707158· Boston Medical Center· Source

• Completed

  Vancomycin Powder and Dilute Povidone Iodine Lavage for Infection Prophylaxis in High Risk Total Joint Arthroplasty

  NCT04075526· Phase 1· NYU Langone Health· Source

• Completed

  A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)

  NCT03940703· Phase 2· EMD Serono Research & Development Institute, Inc.· Source

• Completed

  Treating Chronic Pain in Buprenorphine Patients in Primary Care Settings

  NCT03698669· Boston University· Source

Showing 50 of 86.

Conditions

Diseases this institution publishes on or runs trials for.

• Stroke235 works · 16 trials
• HIV80 works · 13 trials
• Atrial fibrillation67 works · 3 trials
• Chronic kidney disease52 works · 6 trials
• Amyloidosis47 works · 8 trials
• Tuberculosis45 works · 1 trial
• Sickle cell disease13 works · 10 trials
• Peripheral artery disease13 works · 4 trials
• Hepatitis C10 works · 0 trials
• Ventricular tachycardia10 works · 0 trials
• Hydrocephalus8 works · 0 trials
• Chronic lymphocytic leukaemia6 works · 3 trials
• Brain aneurysm5 works · 0 trials
• Mantle cell lymphoma4 works · 0 trials